Document is current
Any future updates will be listed below
-
Authors
Kiene, Franziska https://orcid.org/0000-0002-0462-8095
Notbohm, Annika https://orcid.org/0009-0002-8759-6005
Roheger, Mandy https://orcid.org/0000-0002-6015-3194
Duning, Thomas https://orcid.org/0000-0003-3942-0697
Hildebrandt, Helmut https://orcid.org/0000-0002-9659-1671
-
Funding
Funding for this research was provided by:
Carl von Ossietzky Universität Oldenburg
- License Information
-
More Information
Article History
Received: 6 June 2025
Accepted: 13 February 2026
First Online: 6 March 2026
Declarations
:
: The retrospective re-evaluation project was approved by the ethics committee of the medical board of Bremen (number 905/ 2024) and was performed in accordance with the ethical standards of the Declaration of Helsinki. The informed consent was not necessary due to the retrospective nature of the study, according to §39 BremKrhG.
: Not applicable.
: T.D.: Professional fee for speeches and travel support: Genzyme, Shire, Bristol-Myers Squibb, Boehringer-Ingelheim Pharma, Sanofi Aventis, Eisai, Novartis, Bayer Vital, Merz Pharma, Actelion, Lundbeck, Amicus, Merck-Serono, Lilly, Berlin-Chemie, Roche, Biogen. Advisory fee: Genzyme, Shire, Bristol-Myers Squibb, AstraZeneca, Actelion, Amicus, Novar-tis, Teva, Roche, Biogen. Research fundings: Amicus, Genzyme, Shire, Actelion, Novartis, Roche, Biogen. F.K., A.N., M.R., H.H.: Nothing to declare.
